You are viewing the site in preview mode
Skip to main content
| |
Group E
|
Group C
|
P
|
|---|
|
Subjects, n
|
209
|
228
| |
|
Gender, n (%)
|
|
Male
|
52 (25.0)
|
48 (21.1)
|
0.340
|
|
Female
|
156 (75.0)
|
179 (78.9)
| |
|
Age, y
|
40.66 ± 12.04
|
40.67 ± 11.81
|
0.994
|
|
BMI, kg/m2
|
23.15 ± 2.84
|
23.20 ± 2.87
|
0.847
|
|
Respiration, rpm
|
17.09 ± 1.81
|
17.04 ± 2.18
|
0.808
|
|
Heart rate, bpm
|
74.45 ± 8.43
|
74.48 ± 9.75
|
0.978
|
|
Heart rhythm, n (%)
|
|
Normal
|
207 (99.0)
|
225 (99.1)
|
1.000
|
|
Abnormal
|
2 (1.0)
|
2 (0.9)
| |
|
SBP, mmHg
|
121.63 ± 16.26
|
122.64 ± 16.01
|
0.513
|
|
DBP, mmHg
|
74.92 ± 9.48
|
74.63 ± 8.80
|
0.738
|
|
MAP, mmHg
|
92.91 ± 11.65
|
93.17 ± 10.84
|
0.806
|
- aGroup E was treated with nalbuphine hydrochloride diluted with saline to 1 mg/L. Group C was administered tramadol hydrochloride diluted with saline to 10 mg/L.
